4G3Y
Crystal structure of TNF-alpha in complex with Infliximab Fab fragment
Summary for 4G3Y
| Entry DOI | 10.2210/pdb4g3y/pdb |
| Related | 4G3Z |
| Descriptor | infliximab Fab L, infliximab Fab H, Tumor necrosis factor, ... (4 entities in total) |
| Functional Keywords | tnf, infliximab, immune system |
| Biological source | Homo sapiens (human) More |
| Cellular location | Cell membrane; Single-pass type II membrane protein. Tumor necrosis factor, membrane form: Membrane; Single-pass type II membrane protein. Tumor necrosis factor, soluble form: Secreted. C-domain 1: Secreted. C-domain 2: Secreted: P01375 |
| Total number of polymer chains | 3 |
| Total formula weight | 65187.71 |
| Authors | Liang, S.Y.,Dai, J.X.,Guo, Y.J.,Lou, Z.Y. (deposition date: 2012-07-15, release date: 2013-03-27, Last modification date: 2024-10-30) |
| Primary citation | Liang, S.Y.,Dai, J.X.,Hou, S.,Su, L.,Zhang, D.,Guo, H.,Hu, S.,Wang, H.,Rao, Z.,Guo, Y.J.,Lou, Z.Y. Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab J.Biol.Chem., 288:13799-13807, 2013 Cited by PubMed Abstract: Although infliximab has high efficacy in treating TNFα-associated diseases, the epitope on TNFα remains unclear. PubMed: 23504311DOI: 10.1074/jbc.M112.433961 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.6 Å) |
Structure validation
Download full validation report






